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Preimplantation genetic diagnosis was first successfully performed in 1989 as 
an alternative to prenatal diagnosis for couples at risk of transmitting a genetic 
or chromosomal abnormality, such as cystic fibrosis, to their child. From 
embryos generated in vitro, biopsied cells are genetically tested. From the 
mid-1990s this technology was employed as an embryo selection tool for 
patients undergoing IVF, screening as many chromosomes as possible, in the 
belief that selecting chromosomally normal embryos would lead to higher 
implantation and decreased miscarriage rates. This procedure, 
preimplantation genetic screening (PGS), was initially performed using FISH, 
but 11 randomized controlled trials of screening using FISH showed no 
improvement in IVF delivery rates. Progress in genetic testing has led to the 
introduction of array comparative genomic hybridization, quantitative PCR, 
and next generation sequencing for PGS, and three small randomized 
controlled trials of PGS using these new techniques indicate a modest benefit. 
Other trials are still in progress but, regardless of their results, PGS is now 
being offered globally. In the near future, it is likely that sequencing will be 
used to screen the full genetic code of the embryo. 
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What is PGS? 
 
Preimplantation genetic diagnosis (PGD) was developed in the late 1980s as 
an alternative to prenatal diagnosis for couples at risk of transmitting a genetic 
or chromosomal abnormality to their children (Handyside et al., 1990, Harper 
and Handyside, 1994, Harper, 1996).  Couples go through in vitro fertilization 
procedures to create embryos in vitro, cells are biopsied and analysed by a 
number of genetic tests, such as the polymerase chain reaction (PCR) and 
fluorescent in situ hybridization (FISH).  The majority of PGD cases are for 
common genetic abnormalities, such as cystic fibrosis and haemophilia or 
chromosome abnormalities such as translocations (De Rycke et al., 2015).  
PGD has been a controversial procedure as some feel it is unethical to select 
embryos on their genetic or chromosomal make-up and PGD is not allowed in 
some countries, such as Germany and Switzerland, which do allow prenatal 
diagnosis and termination of pregnancy. 
 
In the mid 1990s several groups used PGD technology as an adjunct to IVF 
as an embryo selection tool mainly for patients with advanced maternal age 
(AMA) or repeated implantation failure (Munné et al, 1995a and b, Verlinsky et 
al. 1995) and this has been called preimplantation genetic screening (PGS). It 
is well established that the prevalence of chromosome abnormalities 
increases with advanced maternal age (Hassold and Hunt, 2009) so applying 
the technique to older women going through IVF is logical as they are going to 
produce a high number of chromosomally abnormal embryos.  The limitations 
have been that women of advanced maternal age produce fewer embryos of 
lower quality, human embryos show a high level of chromosomal mosaicism 
and chromosome abnormalities in embryos may be one cause of implantation 
failure, but there may be other reasons. 
 
This paper outlines the biopsy and genetic testing procedures and discusses 
the randomized controlled trials (RCTs) performed to date. But first, the effect 




It has been difficult to examine chromosomes of human embryos using 
traditional karyotyping methods as embryos are slowly dividing and have a 
small number of cells.  Some early karyotyping studies managed to examine a 
few cells from human embryos and data suggested that embryos exhibited 
chromosomal mosaicism (Angell 1997; Zenzes 1992). With the advent of 
FISH it was possible to examine all of the cells from an embryo but only for a 
few chromosomes (Harper et al, 1995, Munne et al, 1995b).  Because 
embryonic cells contain a high level of cytoplasm, normal karyotype spreading 
techniques for FISH and karyotyping were sub standard.  Coonen et al (1994) 
developed a method of spreading embryos and blastomeres which allowed a 
whole human embryo to be examined by FISH (Harper et al., 1994).  These 
studies showed that human embryos exhibited high levels of mosaicism and 
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“chaotic” embryos, where every nucleus showed a different chromosome 
arrangement (Delhanty et al., 1993, Harper et al, 1995, Munne et al, 1995b).   
 
It is now known that the majority of cleavage stage embryos and blastocysts 
show chromosomal mosaicism (Fragouli and Wells, 2011, Greco et al., 2015).  
This has been an issue for PGD and PGS as the biopsied cell may not be 
representative of the remaining embryo and can lead to false positives and 
false negatives.  The use of next generation sequencing (NGS) for PGS has 
shown that the transfer of mosaic embryos can led to healthy deliveries 




There are three stages when cells can be removed from an embryo for PGD 
and PGS:  polar bodies from the oocyte/zygote, blastomeres from cleavage 
stage embryos and trophectoderm cells from the blastocyst.  At all stages the 
embryo is surrounded by the zona pellucida which needs to be breached to 
allow removal of cells. 
 
The earliest stage of biopsy is polar body biopsy.  Both polar bodies are 
required for diagnosis but the first polar body starts to degenerate soon after 
forming and the second polar body is only extruded at fertilization.  The polar 
bodies can be removed simultaneously (Montag et al, 2009) or sequentially 
(Strom et al, 1998), both procedures having advantages and disadvantages.   
In sequential biopsy, the first polar body is biopsied on day 0, the day of the 
egg collection and the second polar body is biopsied on day 1, after 
fertilization.  This method ensures that both polar bodies are of good quality 
and also allows for identification of polar body 1 and 2 but requires two biopsy 
procedures.  In the simultaneous method, both polar bodies are biopsied on 
day 1 as soon as the second polar body is extruded.  Using this method it is 
often difficult to tell the difference between the two polar bodies and polar 
body 1 may have degenerated.   
 
A limitation of polar body biopsy is that it tests for maternal errors only.  This 
may be an advantage for PGS for advanced maternal age as most of the 
errors are due to maternal meiosis.  Polar body biopsy cannot test for post 
zygotic errors, including post zygotic mosaicism which can be looked on as an 
advantage or a disadvantage.  A disadvantage of polar body biopsy is the 
cost.  Polar body biopsy is very time consuming to the embryology team as 
biopsies need to be done at unsocial hours.  And the diagnosis is expensive; 
if 10 eggs are collected, 20 tests need to be carried out.  Using array CGH 
this is very costly but if NGS is used, it may be cheaper if the samples are 
batched.  Either way, it will still cost more than blastocyst biopsy as from 10 
embryos, we would expect to obtain approximately 5 blastocysts – each 
blastocyst forming one test.  Therefore PGS at the blastocyst stage is about a 
quarter of the cost of polar body biopsy.  As a result of these issues, polar 




The first cases of PGD performed at the Hammersmith Hospital in the UK 
used blastomere aspiration from day 3 cleavage stage human embryos 
(Handyside et al., 1990).  Acid Tyrodes solution was used to breach the zona 
and a small pipette was used to gently aspirate 1-2 cells from the 6-8 cell 
embryo.  Acid Tyrodes was a crude method of zona drilling and was rapidly 
replaced by the use of a non-contact laser.  It was only in the ESHRE PGD 
Consortium data collection for cycles performed in 2004 that the laser was 
used more often that acid Tyrodes (Harper et al, 2008). The laser allows for a 
shorter time period to perform the drilling and more accurate size of the hole.   
At this stage, human embryos are starting to compact and so the procedure 
can be technically difficult.  Ca2+Mg2+ free media is used to reduce 
compaction and aid aspiration (Dumoulin et al., 1998).  
 
Cleavage embryo biopsy was the most widely applied technique for PGD and 
PGS until relatively recently (Harper et al., 2012).   It stopped being so 
popular due to being limited to one cell, mosaicism and the lack of positive 
data from RCTs for PGS. 
 
The majority of PGS is now done using blastocyst biopsy (De Rycke et al., 
2015).  In IVF, culturing embryos to the blastocyst stage is considered to be a 
method of embryo selection as only good quality embryos will reach the 
blastocyst stage (Bolton et al., 2015). For blastocyst biopsy, the zona can be 
breached on day 3 or day 5 (Kokkali et al, 2005, McArthur et al, 2005).  The 
embryos are returned to culture and the trophectoderm cells start to herniate 
through the hole.  On day 5, bout 5 trophectoderm cells are cut from the 
embryo.   
 
There are several advantages of using blastocyst biopsy for PGS.  
Blastocysts are less mosaic, there are more cells to analyse which makes the 
diagnosis more accurate, there are fewer embryos to analyse which makes it 
cheaper and blastocyst transfer is a method of embryo selection in itself as 
almost half of embryos will not develop to the blastocyst stage, and since 
PGS is a selection method, it makes sense to test those embryos that are 
already selected and finally, in almost all PGS cases, embryo transfer is done 
at the blastocyst stage.   
 
Vitrification of human embryos has been shown to be a very efficient 
technique (Vajta and Kuwayama 2006, Chang et al., 2011).  Vitification allows 
efficient cryopreservation of embryos either before or after the biopsy.  A cost 
effective way of performing PGS is to biopsy and then vitrify embryos which 
allows more time for the diagnosis and also batching of samples which makes 
the diagnosis much cheaper. It also allows the samples to be sent to another 
location, even country, for the diagnosis (Harton et al., 2010). 
 
PGS has been separated into two versions: version 1: the use of FISH 
examining a few chromosomes and version 2: comprehensive chromosome 
screening. 
 
PGS version 1, FISH and cleavage stage biopsy 
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From 1995 to 2010, PGS version 1 used fluorescent in situ hybridisation on 
polar bodies or cleavage stage embryos (Munne et al, 1995a and b, Verlinsky 
et al, 1995).   Numerous papers claimed that the technique worked and 
thousands of cycles were conducted worldwide.  From 2004-2010, eleven 
randomised controlled trials showed that this technique did not result in an 
increase in delivery rates; some studies showing a significantly reduced 
delivery rate (Staessen et al., 2004, 2008; Stevens et al., 2004; Mastenbroek 
et al., 2007; Blockeel, 2008; Hardarson et al., 2008; Mersereau et al., 
2008; Debrock et al., 2008; Meyer et al., 2009; Schoolcraft et al.,2009, Jansen 
et al., 2008).  At this time, the ESHRE PGD Consortium, the ASRM and the 
BFS wrote statements that PGS using FISH and cleavage stage biopsy was 
unproven and that RCTs should be conducted on polar bodies and 
trophectoderm biopsy using efficient methods that analysed all chromosomes 
(Harper et al, 2010, Anderson and Pickering, 2008, The Practice Committee 
of the Society for Assisted Reproductive Technology and the Practice 
Committee of the American Society of Reproductive Medicine, 2008). 
 
Four reasons have been put forward to explain the failure of PGS version 1.  
First is the FISH technique, which when applied to one cell, is not a very 
efficient procedure and only gives about 80-95% specificity, depending on the 
number of probes used.  Second the high level of mosaicism in cleavage 
stage embryos may mean that an abnormal cell is removed from an otherwise 
normal embryo which may have implanted.  Thirdly, the biopsy of cells from 
an embryo may have a negative effect on implantation which may out-weigh 
the benefits of putting back a chromosomally normal embryo.  And lastly, 
most studies have concentrated on poor prognosis patients (mainly advanced 
maternal age), who produced few embryos usually of poor quality.   
 
PGS version 2, comprehensive chromosome screening  
 
In recent years new technologies have emerged that are more efficient than 
FISH and allow analysis of all of the chromosomes from interphase nuclei.  
PGS version 2 involves using these methods, such as array comparative 
genomic hybridisation (a-CGH) (Geraedts et al, 2011, Magli et al, 2011, 
Mamas et al., 2012), NGS (Fiorentino et al 2014A and 2014B, Bono et al 
2015, Tan et al 2014, Huang et al., 2016) and quantitative PCR (Forman et al, 
2013, Scott et al, 2013). For PGS v2, as well as applying the technique to 
poor prognosis patients, such as advanced maternal age and repeated IVF 
failure, good prognosis patients have been included.    Due to the problems of 
post zygotic mosaicism seen using cleavage stage biopsy, most, but not all, 
groups have concentrated on polar body and blastocyst biopsy (De Rycke et 
al., 2015).    
 
After validation of a-CGH for PGS (Magli et al., 2011, Geraedts et al., 2011) 
ESHRE (European Society of Human Reproduction and Embryology) has 
embarked on a multi-centre RCT for patients with advanced maternal age 
using polar body biopsy.  Polar body biopsy using a-CGH is an expensive 
technique as both polar bodies need to be analysed.  But the technique will 
not be confused by post zygotic mosaicism which may be an advantage or 
disadvantage.  The results should be published in 2017. 
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Three RCTs have been reported using trophectoderm biopsy on good 
prognosis patients and shown an increase in ongoing pregnancy rates (Yang 
et al., 2012, Forman et al., 2013 and Scott et al., 2013.  The size of all three 
studies was small: 55, 89 and 72 patients in the treatment group respectively.  
The limited sample size makes it impossible to draw firm conclusions from the 
three trials but they indicate a modest benefit from embryo selection using 
trophectoderm biopsy (Dahdouh et al., 2015, Lee et al., 2014). Lee et al., 
(2014) concluded that “high-quality experimental studies using intention-to-
treat analysis and cumulative live birth rates including the comparative 
outcomes from remaining cryopreserved embryos are needed to evaluate the 
overall role of PGS in the clinical setting”.   But globally PGS accounts for 
more than all the other indications for PGD added together, according to the 
USA data (Chang et al., 2016) and the ESHRE PGD Consortium Data (De 
Rycke et al., 2015).  Kushnir et al., (2016) reanalysed the SART data and 
concluded that PGS decreased the chances of live birth and that the 
improvements reported were likely to be as a consequence of patient 
selection.  
 
If poor prognosis patients are undergoing PGS, such as those of advanced 
maternal age who by definition produce few embryos, a trend in many IVF 
units is to bank embryos by vitrifying all the embryos from several cycles of 
IVF before warming all the embryos and performing the biopsy and diagnosis.   
In some USA centres it is routine for patients to go through four egg 
collections before PGS is applied.  From this cohort – there is an increased 
chance that a ‘normal’ embryo will be found, leading to increased pregnancy 
rates per embryo transfer procedure but very low pregnancy rates per egg 
collection (Orris et al., 2010).   
 
Next generation sequencing (NGS) is rapidly becoming the technique of 
choice for PGS and for the detection of chromosomal imbalances in patients 
with translocations (Fiorentino et al 2014A and 2014B, Li et al., 2015, Tan et 
al., 2014, Huang et al., 2016) with improved results compared to a-CGH 
(Yang, et al., (2015), Fiorentino et al., 2014B).  Hopefully very soon larger, 
well-designed RCTs using a-CGH and/or NGS on trophectoderm cells will be 
published (Harper et al., 2016).  Indeed these studies will be welcome, so that 
the controversy surrounding PGS can finally be put to rest, but until they are 





Medical screening is established in pregnant women, children, and adults. In 
screening embryos there is the same need to ensure efficiency and safety. 
IVF is a multi billion dollar business throughout the world, using technology 
that advances quickly. Because many techniques are introduced without 
proper validation or efficacy testing (Harper et al, 2011, Harper et al., 2017), 
there are instances of technology which has been shown not to work after it 
has been applied to thousands of IVF patients, who have generally paid for 
the privilege. IVF patients are emotionally vulnerable and after several failures 
are often willing to trial new procedures. When talking to patients about PGS, 
health professionals must discuss the advantages and disadvantages of PGS 
(Garcia-Velasco and Fauser, 2016) and practice evidence based medicine. 
The refinement of sequencing will allow more genetic information to be 
obtained, and this technology is already in use in PGD for monogenic 
disorders with simultaneous aneuploidy screening (Yan et al 2015, Gui et al, 
2016). It is highly probable that in the future all IVF embryos will undergo 
genetic testing using sequencing to determine which embryos are the ‘best’ 
from the cohort produced. Whatever the outcome of the PGS RCTs, patients 
may decide that it is beneficial to know the genetic make up of their embryos 
(Hens et al, 2013). Indeed, PGS is already applied to every embryo for every 
patient in some IVF clinics. PGS will finally fit its name, with PGD and PGS 
merging as the same technique, and will determine aneuploidy and genetic 
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